Tassorelli, C
Bragg, S
Krege, JH
Doty, EG
Ardayfio, PA
Ruff, D
Dowsett, SA
Schwedt, T
Funding for this research was provided by:
Eli Lilly and Company (Study sponsored by Eli Lilly and Company)
Article History
Received: 17 August 2021
Accepted: 19 October 2021
First Online: 6 November 2021
Declarations
:
: The study received approval from the relevant Ethics Committees and participants provided written informed consent for study participation. The study was conducted in accordance with the Declaration of Helsinki. A list of ethics review committees are provided in the supplement.
: Not applicable
: CT has received fees for advisory boards or scientific lecturing from Allergan/Abbvie, Eli Lilly and Company, Novartis, and TEVA; and institutional payments for clinical trials from Allergan/Abbvie, Eli Lilly and Company, Novartis, and TEVA. SB, JHK, EGD, PAA, DR, SAD are full time employees and minor stockholders at Eli Lilly and Company. Within the prior 24 months, TS has consulted with Alder, Allergan, Amgen, Biohaven, Click Therapeutics, Eli Lilly and Company, Equinox, Ipsen, Lundbeck, Novartis, Tonix, Weber and Weber, and XoC; received research grants from Amgen; and has stock options with Aural Analytics and Nocira.